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Cytokine  Act ivat ion During Attacks of  the H yper im m unog lobu l inem ia  D and  
Periodic  Fever Syndrome
By Joost P.H. Drenth, Marcel van Deuren, Johanna van der Ven-Jongekrijg, Casper G. Schalkwijk,
and Jos W.M. van der Meer
T h e  h y p e r i m m u n o g l o b u l i n e m i a  D a n d  p e r i o d i c  f e v e r  (h y p e r -  
IgD) s y n d r o m e  is t y p i f i e d  b y  r e c u r r e n t  f e b r i l e  a t t a c k s  w i t h  
a b d o m i n a l  d i s t r e s s ,  j o i n t  i n v o l v e m e n t  ( a r t h r a l g i a s / a r t h r i t i s ) ,  
h e a d a c h e ,  sk in  l e s i o n s ,  a n d  a n  e l e v a t e d  s e r u m  IgD level  
( > 1 0 0  U /m L ) .  T h i s  f am i l ia l  d i s o r d e r  h a s  b e e n  d i a g n o s e d  in 
59 p a t i e n t s ,  m a i n l y  f r o m  E u r o p e .  T h e  p a t h o g e n e s i s  of  t h i s  
f e b r i l e  d i s o r d e r  is u n k n o w n ,  b u t  a t t a c k s  a r e  j o i n e d  b y  a n  
a c u t e - p h a s e  r e s p o n s e .  B e c a u s e  t h i s  r e s p o n s e  is c o n s i d e r e d  
t o  b e  m e d i a t e d  b y  c y t o k i n e s ,  w e  m e a s u r e d  t h e  a c u t e - p h a s e  
p r o t e i n s  C - r e a c t i v e  p r o t e i n  (CRP) a n d  s o l u b l e  ty p e - l l  p h o s -  
p h o l i p a s e  A2 (PLA2) t o g e t h e r  w i t h  c i r c u l a t i n g  c o n c e n t r a t i o n s  
a n d  e x  v ivo  p r o d u c t i o n  of  t h e  p r o i n f l a m m a t o r y  c y t o k i n e s  
i n t e r l e u k i n - 1 «  (IL-lo'), IL-1 [ } ,  IL-6, a n d  t u m o r  n e c r o s i s  f a c t o r  
a  (TNFcv) a n d  t h e  i n h i b i t o r y  c o m p o u n d s  IL-1 r e c e p t o r  a n t a g ­
o n i s t  (IL-1 ra),  IL-10, a n d  t h e  s o l u b l e  TNF r e c e p t o r s  p 5 5  (sTNFr 
p55)  a n d  p 7 5  (sTNFr  p75)  in 22  p a t i e n t s  w i t h  t h e  h y p e r - l g D  
s y n d r o m e  d u r i n g  a t t a c k s  a n d  r e m i s s i o n .  S e r u m  CRP a n d  
PLA2 c o n c e n t r a t i o n s  w e r e  e l e v a t e d  d u r i n g  a t t a c k s  ( m e a n ,
213  m g / L  a n d  1 ,452  n g / m L ,  r e s p e c t i v e l y )  a n d  d e c r e a s e d  b e ­
t w e e n  a t t a c k s .  P l a s m a  c o n c e n t r a t i o n s  o f  IL-1«, IL-1 f i ,  o r  IL- 
10 w e r e  n o t  i n c r e a s e d  d u r i n g  a t t a c k s .  T N F «  c o n c e n t r a t i o n s  
w e r e  s l ig h t ly ,  b u t  s ig n i f i c a n t ly ,  h i g h e r  w i t h  a t t a c k s  (104 v  
117 p g / m L ) .  C i r c u l a t i n g  IL-6 v a l u e s  i n c r e a s e d  w i t h  a t t a c k s  
(19.7 v  147 .9  p g / m L )  a n d  c o r r e l a t e d  w i t h  CRP a n d  PLA2 v a l ­
u e s  d u r i n g  t h e  f e b r i l e  a t t a c k s .  T h e  v a l u e s  of  t h e  a n t i i n f l a m ­
m a t o r y  c o m p o u n d s  IL-1ra, s T N F r  p 5 5 ,  a n d  s T N F r  p 7 5  w e r e  
s i g n i f i c a n t l y  h i g h e r  w i t h  a t t a c k s  t h a n  b e t w e e n  a t t a c k s ,  a n d  
t h e r e  w a s  a s i g n i f i c a n t  p o s i t i v e  c o r r e l a t i o n  b e t w e e n  e a c h .  
T h e  e x -v iv o  p r o d u c t i o n  o f  T N F « ,  IL-1 (3 , a n d  IL-1ra w a s  s i g ­
n i f i c a n t ly  h i g h e r  w i t h  a t t a c k s ,  s u g g e s t i n g  t h a t  t h e  m o n o ­
c y t e s / m a c r o p h a g e s  w e r e  a l r e a d y  p r i m e d  in v iv o  t o  p r o d u c e  
i n c r e a s e d  a m o u n t s  o f  t h e s e  c y t o k i n e s .  T h e s e  f i n d i n g s  p o i n t  
t o  a n  a c t i v a t i o n  o f  t h e  c y t o k i n e  n e t w o r k ,  a n d  t h i s  s u g g e s t s  
t h a t  t h e s e  i n f l a m m a t o r y  m e d i a t o r s  m a y  c o n t r i b u t e  t o  t h e  
s y m p t o m s  of  t h e  h y p e r - l g D  s y n d r o m e .
© 1 9 9 5  b y  T h e  A m e r i c a n  S o c i e t y  o f  H e m a t o l o g y .
T HE HYPERIMMUNOGLOBULINEMIA D and peri­
odic fever syndrome (hyper-lgD) is a rare entity char­
acterized by periodic occurrence of febrile attacks.1 All pa­
tients have a clearly elevated (poly)clonal serum IgD (> 100 
U/mL). So far. we have diagnosed 59 patients (31 male 
and 28 female) from nine, mainly European, countries. The 
episodes last 3 to 7 days, occur every 4 to 6 weeks, start 
early, and persist throughout life. and. between attacks, pa­
tients are nonsymptomatic.2 Symptoms are not triggered by 
known infectious agents and include abdominal distress 
(vomiting, diarrhea, and pain), joint involvement (arthralgia/ 
arthritis), skin lesions, headache, and lymphadenopathy. 2 4 
The main feature of the disease is the abrupt onset of fever 
that parallels with an acute-phase reaction as evidenced by 
leukocytosis, neutrophilia, and a raised erythrocyte sedimen­
tation rate.
The pathogenesis of the hyper-lgD syndrome is unclear, 
but, because fever and the acute-phase reaction are consid­
ered to be mediated by cytokines such as interleukin-\/3 (IL- 
\p), IL-6, and tumor necrosis factor a (TNFa), it can be 
speculated that symptoms in the hyper-lgD syndrome result
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from a disturbed cytokine synthesis which may be responsi­
ble for some of its clinical manifestations and could also 
contribute to the polyclonal serum IgD elevation.v? There­
fore, we studied the pattern of circulating and ex vivo pro­
duction of inflammatory mediators IL-1 a, IL-1/3, IL-6, 
TNFa, C-reactive protein (CRP), soluble type-11 phospholi- 
pase A: (PLA: ), and inhibitory compounds such as IL-1 
receptor antagonist (IL-lra), IL-I0. and soluble TNF recep­
tors p55 (sTNFr p55) and p75 (sTNFr p75).
MATERIALS AND METHODS
Patients. The study group consisted o f  22 Dutch patients, 14 
male and 8 female patients, with the hyper-lgD syndrome. The mean 
age at the time o f  the study was 28.3 years (SD ±  14.4 years). The 
diagnosis was made following standard clinical criteria, and a recent
C  c
review with a pertinent description o f  the clinical and biologic tea- 
turcs o f  the hyper-lgD syndrome has been published elsewhere.“ 
Briefly, all patients were suffering from recurrent febrile attacks 
accompanied by a combination of  the following features: lymphade­
nopathy, splenomegaly, arthralgias/arthritis, abdominal pain/vom­
iting/diarrhea, and skin lesions. The attacks are self-limiting and last 
3 to 7 days. The main clinical features o f  these patients are listed 
in Table 1.
Blood samples. Sampling o f  plasma was performed during at­
tacks as well as during remission, using special endotoxin-free tubes 
(Vacutainer Systems; Becton Dickinson, Rutherford, NJ). The 
plasma was immediately processed to avoid ex vivo cytokine excre­
tion.s We defined attacks if the patient was febrile ( >38°C  not caused 
by infection) and showed signs of  active disease with symptoms as 
mentioned before. Remission was defined as the absence o f  sym p­
toms for at least I month. No medication, including antipyretics, 
were allowed during the study period. All patients underwent physi­
cal examination, and results are listed in Table 1. Cytokine produc­
tion was measured using a whole blood culture system as described 
elsewhere.*' Briefly, two 4-mL tubes containing 48 pL  IEDTA-K, 
and 250 pL  aprotinin ( I (),()()() kallikrein-inactivaling units per niL; 
Bayer, Leverkusen, Germany) were drawn.
One tube was incubated immediately; the other tube was incubated 
after addition o f  50 pL  lipopolysaccharide (LPS; Escherichia coli 
serotype 055:B5, final concentration 10 p g/mL; Sigma, St Louis,
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Table 1. Main Clinical Features of 22 Patients With the Hyper-lgD and Periodic Fever Syndrome
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Patient No. Sex Age (yr) Lymphadenopathy Splenomegaly Abdominal Distress Skin Lesions Arthritis
1 F 32 + - + + +
2 M 30 + + + +
3 M 34 - + + +
4 M 69 — - + -
5 F 42 + - — + -
6 M 49 + - + + +
7 M 35 + + + + +
8 M 36 +
•
+ + + +
9 F 24 + — -f - —
10 F 43 + + - - —
11 M 20 + — + + +
12 F 16 + — + + —
13 F 22 + — ----- ----- +
14 M 13 + 4 - + + +
15 M 21 + ---- + + +
16 M 8 + ----- + + +
17 M 12 + ---- + + +
18 M 31 + ----- + + +
19 M 27 + + + +
20 M 7 + ----- + + —
21 F 24 + ----- + + +
22 F 27 + + + + +
Abbreviations: + , present; - ,  absent; M, male; F, female.
MO). After 24 hours of  incubation at 37°C both tubes are centrifuged 
at 2.2501* for 10 minutes and. second, at 15,000,? for 5 minutes to 
obtain platelet-poor plasma. Aliquots were stored at - 7 0 ° C  until 
assay. Cytokine production with LPS stimulation was measured and 
compared with production without LPS stimulation. Control values 
were obtained from 10 healthy volunteers (20 to 45 years o f  age) 
and were 6,847 ±  2,175 pg/mL (IL-1/?); 3,344 ±  969 pg/mL 
(TNFa),  and 9,827 ±  2,597 pg/mL (IL-lra).  T N F a  was determined 
by radioimmunoassay as described by Van der Meer et a l10 (lower 
detection level, 20 pg/mL; upper detection limit, 10,000 pg/mL). 
IL-1 a  and IL-1 ¡3 were measured by radioimmunoassay (without 
chloroform extraction) according to Lisi et a l"  ( I L - l a  lower detec­
tion limit, 5 pg/mL; IL-1/? lower detection limit, 40 pg/mL). IL-lra  
was determined by radioimmunoassay according to Poutsiaka et a l12 
(lower detection limit, 60 pg/mL). sTNFr were measured by an 
enzyme-linked immunosorbent assay (ELISA [detection level. 80 
pg/mL for sTNFr p55 and 300 pg/mL for sTNFr p75|; a kind gift 
of  H. Gallati, Hoffmann-La Roche, Basel, Switzerland). This assay 
measures both free and total receptor-bound concentrations. Because 
sTNFr is not produced ex vivo, its LPS-stimulated production was 
not assessed in this study. IL-6 was measured by an ELISA as 
described earlier (detection level, 14 pg/m L).13 IL-I0 was measured 
by sandwich ELISA with the 4G6 and 5D1 I mouse antihuman IL- 
10 monoclonal antibodies for capture and the 5A10 antihuman IL-10 
monoclonal antibodies for detection (kindly provided by Mcdgcnix, 
Amersfoort, The Netherlands). The detection limit was I I pg /m L.14
CRP measurements were performed with an immunoturbidimetric 
assay using an automatic analyzer HITACHI 747 (Hitachi Co, 
Tokyo, Japan). The measuring range was from 3 to 440 mg/L.
Secreted nonpancreatic type-11 PLA2 antigen concentrations in 
plasma were determined with an ELISA modified from Smith et 
a l .1-’ Two different monoclonal antibodies against human PLA2 (a 
kind gift from Dr F.B. Taylor, Jr, Oklahoma Medical Research Foun­
dation, Oklahoma City, OK) were used as coating and catching 
antibodies. Because previous experiments showed a very good corre­
lation between results from ELISA measurements and those obtained 
with cultured medium from Hepatoma G2 cells stimulated with hu­
man IL-6, only the former method was used (Schalkwijk CG. unpub­
lished observations). The lower limit of detection was I ng/mL. To 
minimize analytical errors, all samples from the same patient were 
analyzed in the same run in duplicate.
Statistical analysis. The paired nonparametric Wilcoxon signed 
rank test was used for statistical comparison o f  values obtained 
during active disease versus remissions. The unpaired nonparametric 
Mann-Whitney U test was used where appropriate. In patients with 
multiple samples taken during separate episodes of active disease, 
the mean value was used. Probability (P) values were calculated on 
the basis of  two-tailed tests. A correlation coefficient was calculated 
with the Pearson's correlation test. A P value o f  less than .05 was 
considered to be the lowest level of  significancy. Data are given in 
mean ±  standard deviation (SD).
RESULTS
Results of circulating cytokines and other inflammatory 
mediators are given in Figs 1 and 2. The CRP concentrations, 
a reflection of the acute-phase response, clearly modulated 
with the attacks in the patients with the hyper-lgD syndrome. 
The CRP concentrations were uniformly high during attacks 
(213.3 ± 98.2 mg/L) but decreased to low values (22.6 ± 
26.8 mg/L) in between attacks (P <  .0001; see Fig 1A). 
Concentrations of PLA2 increased to a mean of 1,452 ± 
1,665 ng/mL during the febrile attacks, as compared with 
values during nonsymptomatic periods (113 ± 240 ng/mL; 
P <  .0001; see Fig IB). One patient even had a 253-fold 
elevation (maximum, 6,066 ng/mL) of PLA2 during attack 
as compared with convalescence. The concentrations of 
PLA2 and CRP obtained during febrile attacks showed a 
very good correlation during attacks (/* = 0.74; P <  .0001).
We could not detect measurable quantities of circulating 
IL-1 a  between and during attacks in patients with the hyper- 
lgD syndrome (Table 2). The mean plasma concentrations 
of IL-1/? durinc active disease did not differ from the values
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Fig 1. Individual serum CRP 
(A) and PLA2 (B) for 22 hyper-lgD  
patients during and in between 
attacks. For (A), the vertical lines 
indicate mean (•) ± SD. The ver­
tical lines in (B) indicate median 
{♦ ) and 95% confidence inter­
vals. The increase was statisti­
cally significant for CRP and PLA2 
[P <  .0001).
obtained during remissions. The TNF« concentrations in- 
creased from 104 ± 20 pg/mL to I 17 ± 15 pg/mL, a small 
but significant increase (P = .0075). Nevertheless, (he TNFa 
concentrations during attack remained within normal values 
of our laboratory (106 ± 25 pg/mL). IL-6 was also signifi­
cantly elevated during active disease (147.9 ± 258.3 pg/mL; 
P <  .0001; see Fig 2A). Three patients had values above 
150 pg/mL (471, 720, and 1.074 pg/mL, respectively). Ex­
clusion of data from these 3 patients did result in a lower 
mean IL-6 plasma concentration during attacks (54.9 ± 27.2 
pg/mL). However, the difference between values obtained 
during attacks and between attacks remained significant do- 
spite exclusion (P <  .0001). During febrile episodes, there 
was a moderate, albeit significant, correlation between IL-6 
and the acute-phase proteins CRP (r = 0.47; P = .014) and 
PLA2 (/• = 0.45; P = .018).
No correlation could be detected between IL-6 and either 
IL-1/? or TNFa.
IL-10, measured in plasma of 8 patients, remained un­
changed regardless of the phase of the disease (Table 2).
The anti-inflammatory compounds IL-1 ra. sTNFr p55, and 
sTNFr p75 were significantly increased during attacks com­
pared with remissions (Fig 2B through D). The mean values 
of IL-lra were 996 ± 329 pg/mL during attacks, whereas 
they were 300 ± 167 pg/mL during remission (P <  .0001; 
see Fig 2B). The mean sTNFr p55 and sTNFr p75 concentra­
tions during active disease increased to 5,043 ± 1,703 pg/ 
mL and 7,103 ± 2,378 pg/mL, respectively (both P <  .0001; 
see Fig 2C and D). The sTNFr p75/sTNFr p55 ratio did not 
change with attacks (data not shown). We could not establish 
a correlation between either the individual concentrations of 
IL-lra, sTNFr p55, or sTNFr p75 and the temperature at the 
time of blood drawing or the frequency of the attacks (data 
not shown). During attacks, there was a significant correla­
tion between circulating plasma concentrations of IL-lra and 
sTNFr p55 (/• = 0.48; P = .0231), IL-lra and sTNFr p75 (r
= 0.67; P = .0006), and sTNFr p55 and sTNFr p75 (r =
0.58; P = .0041); however, no correlation could be detected 
between individual CRP levels and IL-lra, sTNFr p55, or 
sTNFr p75 levels. In 3 patients, the course of the circulating 
IL-lra, sTNFr p55, and sTNFr p75 concentrations during 
the first 5 days after onset of the attack was followed as 
shown in Fig 3. The course of values for the various cyto­
kines is as follows. sTNFr p55 and sTNFr p75 only decrease
3 days after onset of the febrile attack. IL-lra reaches the 
highest values on the second day of the attack and normalizes 
within 5 days. IL-6 was rapidly cleared from the circulation, 
similar to the acute-phase proteins CRP and PLA2.
Ex vivo cytokine production. Figure 4, upper panel, 
shows the nonstimulated production of the various cytokines 
tested. The unstimulated production of TNFa between at­
tacks was significantly higher as compared with that for 
healthy controls (564 ± 304 v 225 ± 1 1 pg/mL). Only the 
values for IL-lra were significantly higher during attacks 
than during remissions, 3,642 ± 1708 pg/mL as compared 
with 2,048 ± 2,398 pg/mL (P = .015). The production of 
IL-1 a  in whole blood in the presence or absence of LPS 
was negligible and did not differ between attacks and remis-
C  L r
sion. The LPS-stimulated production of IL-1/3 and TNFa in 
patients with the hyper-lgD was significantly higher during 
attacks as compared with that in remissions and for healthy 
controls (Fig 4. lower panel; P <  .0001). During remissions, 
both the unstimulated and LPS-stimulated production of 
TNFa. but not of IL-1 (3. was significantly higher compared 
with that of controls (P <  .05). Fourteen patients had TNFa 
concentrations beyond the upper detection limit of 10.000 
pg/mL during attacks, compared with only 6 patients during 
remission. LPS-stimulated production of IL-6 during attacks 
was similar to that measured during nonsymptomatic peri­
ods. The LPS-stimulated production of IL-lra was also sig­
nificantly higher during attacks than in between attacks and 
than that in healthy volunteers (P <  .0001).
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Fig 2. Circulating IL-6 (A), IL- 
lra  (B), sTNFr p55 (C), and sTNFr 
p75 (D) in 22 hyper-lgD patients. 
The individual values are repre­
sented by black dots and were  
obtained during and between at­
tacks. In (A), the vertical lines in­
dicate median ( ♦ ) and 95% con­
fidence intervals. For (B through  
D), the vertical lines are the 
mean (•) ± SD. The increase was 
statistically significant for all 
four cytokines (P <  .0001).
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During attacks, there were modest correlations between 
IL-lra and IL-lf3 production (/* = 0.42; P = .027) and IL- 
lra and IL-6 production (r = 0.3; P = .027). The production 
of IL-If3 correlated well with that of IL-6 during febrile 
episodes (r = 0.53; P = .0057).
DISCUSSION
We investigated the pattern of circulating cytokines and 
the ex vivo production of cytokines in 22 patients with the 
hyper-lgD syndrome. We found evidence for a vigorous 
acute-phase response in the hyper-lgD syndrome, as re­
flected by the significant increase of CRP and PLA: concen­
trations that subsided during remission. The significant ele­
vation of the proinflammatory cytokines IL-6 and, albeit very 
modest, TNFcv together with the elevation of the natural 
cytokine inhibitors IL-lra, sTNFr p55, and sTNFr p75 point 
to activation of the cytokine network during the attacks of 
the hyper-lgD syndrome. Although it is not clear to what 
extent these cytokines contribute to the clinical features of 
the hyper-lgD syndrome, many of its symptoms are compati­
ble with the effects of proinflammatory cytokines. However, 
it is unlikely that only one factor can cause the clinical 
picture; instead, activation of the cytokine network and 
involvement of various cytokines probably contribute to the 
pathogenesis of the attacks.
The elevation of these inflammatory mediators occurs re-
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Table 2. Circulating Cytokines in 22 Patients
With Hyper-lgD Syndrome
Cytokine
Circulating Concentration (pg/mL) ± SD
Between Attacks Attack
IL-1a < 5 < 5
IL-1/? 83.1 ±  20.3 80.4 ± 21.6
IL-10* 20.3 ± 21.1 14.8 ± 3.7
* Tested in 8 patients.
gardless of the severity of attacks, as reflected by body tem­
perature and CRP concentrations or the frequency of attacks. 
The absence of any elevation oi'IL-10 concentration, a potent 
inhibitor of synthesis of cytokines, argues against an im­
portant role for this cytokine in the pathogenesis of the 
hyper-lgD syndrome.16 Lastly, there is increased ex vivo 
production of IL-1/?, TNFa, and IL-lra during attacks com­
pared with nonsymptomatic periods, as measured in a whole 
blood culture system.
The acute-phase response in humans is considered to be 
mediated by the proinflammatory cytokines, and we detected 
a modest but significant elevation of IL-6 together with a 
significant correlation between IL-6 and the acute-phase pro­
teins CRP and PLA2 in the blood during the febrile attacks.
In view of these findings, it can be speculated that the 
increased plasma IL-6 concentration results from overpro­
duction rather than underutilization, because renal function 
was normal in all patients. In addition, the elevated IL-6 
values are associated with increased CRP and PLA2 values. 
Underutilization would probably have resulted in low con­
centrations of these acute-phase proteins. IL-6, as the major 
mediator for the regulation of acute-phase protein synthesis 
in humans, also influences the glycosylation of these pro­
teins.71718 In recent studies in the hyper-lgD syndrome, we 
have shown elevated a r t  fucosylation of the acute-phase 
protein a,-acid glycoprotein (AGP), and this finding is com­
patible with a role of IL-6 during the recurrent febrile at­
tacks.11’ In addition, IL-6 is a stimulus for PLA2 synthesis in 
the liver, and the strongly elevated (13-fold) PL.A2 concentra­
tions found during the febrile attacks, together with the corre­
lation between IL-6 and PLA2, corroborate with these find­
ings.20 By cleavage of arachidonic acid from cell membrane, 
PLA2 in its turn is able to elicit an inflammatory response. 
Enhanced PLA2 activity in serum propagates tissue damage 
through membrane digestion and liberation of cytotoxic fatty 
acids.21 For example, when administered intra-articulary in 
rats, it causes synovitis,22 and serum PLA2 concentrations 
correlate well with activity of juvenile rheumatoid arthritis 
(JRA) in humans.23 Furthermore, intradermal injection of 
PLA2 causes local dermal inflammatory infiltrates.24 These 
biologic effects of PLA2 may be responsible for some of the 
clinical features of the hyper-lgD syndrome, because arthritis 
and cutaneous vasculitis are main symptoms of the disease.2,3
Despite our efforts, we have not been able to establish 
which endogenous pyrogen is responsible for the fever in 
the hyper-lgD syndrome.
A possible reason for our failure to trace appreciable ele­
vations of pyrogenic proinflammatory cytokines such as IL-
\P and TNFa may be the delay between onset of attack and 
sampling. Although we sampled all our patients on their first 
day with fever, this may already have been too late. The 
slight elevation of TNFa during attacks perhaps reflects the 
descending slope of an earlier peak. The increased CRP 
levels at time of drawing of blood indicate an already ongo­
ing acute-phase response thought to be the consequence of 
the action of cytokines, and these may have already disap­
peared from the circulation. This hypothesis is in line with 
the finding of increased cytokine inhibitors such as IL-lra, 
sTNFr p55, and sTNFr p75, of which it is known, from 
experimental endotoxemia, that they can still be detected in 
the circulation hours after the disappearance of IL-1 (5 and 
TNFa.25'27 The same holds for PLA2, which peaks 18 to 24 
hours later than TNFa after endotoxin infusion in human 
volunteers.28
In our study, elevation of IL-lra, sTNFr p55, and sTNFr 
p75 was present at the first day of an attack, and appreciable 
concentrations were found on the second and third day of 
the attack. Endogenously produced IL-lra, a major natural 
inhibitor of IL-1, may ameliorate the severity of attacks in 
the hyper-lgD syndrome.29'31 Because we did not find clear 
elevations of IL-1 concentrations, it is impossible to judge 
whether the amount of IL-lra is adequate to alleviate the 
acute inflammation. Our finding of predominant concentra­
tions of IL-1 antagonist recalls the results obtained in sys­
temic JRA. another periodic febrile disorder. In JRA, inhibi­
tion of IL-1 bioactivity by serum and urine during febrile 
attacks was found.32 Also, for TNFa, we merely find inhibi­
tion, as judged by the elevated concentrations of soluble 
receptors for TNF.33 sTNFrs bind TNF and form a biologic, 
inactive complex, blunting the deleterious effects of TNFa.26
How do our results of circulating cytokines compare with 
measurements in another periodic fever syndrome such as 
familial Mediterranean fever (FMF)? In FMF patients, TNF 
and IL-1 activity has been investigated.
In a study with Sephardic Jews with FMF there was no 
evidence of TNFa bioactivity in plasma obtained during 
attack and remission.34 Nevertheless, the investigators sug­
gested a role for TNFa in FMF and impute the lack of 
elevated circulating plasma TNFa to the short half life (6 
minutes) and the possible binding to soluble receptors. In a 
similar study of Turkish FMF patients, using ELISA, TNFa 
was detected, albeit in modest concentrations (33.1 pg/mL 
in between attacks compared with 62.2 pg/mL during at­
tacks).35 Here, again, one may wonder whether the values 
measured during an attack represent a tail of initially elevated 
TNF concentrations. The higher concentrations we found 
during remissions (104 ± 20 pg/mL) and attacks (117 ± 15 
pg/mL) in the hyper-lgD syndrome are most likely due to 
detection of both free TNF and TNF bound to sTNFr.
The role of IL-1 was tested in a study of 18 FMF patients, 
9 symptomatic and 9 asymptomatic, and mean IL-1 activity 
in patients (either during attack or remission) was compara­
ble with the values obtained in controls.36
We studied the effect of bacterial LPS on the cytokine 
production as generated in whole blood. In contrast to T- 
cell mitogens such as concavalin A, in our experience, LPS 
is a reliable stimulator of cytokine production. The effect of
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LPS is dose-dependent, and dosages at 10 /vg/mL as used in 
our study have yielded reproducible results.37 It is of interest 
that we detected an augmented LPS-stimulated ex vivo pro­
duction of TNFa, IL-1/?, and IL-lra in our whole blood 
culture system during attacks.
This enhanced production capacity in the hyper-lgD syn­
drome during attacks is in contrast with findings obtained in 
various infectious diseases such as meningococcal sepsis and 
typhoid fever, where the ex vivo production of TNF, IL-1, 
and IL-6 is depressed during the acute stage and is gradually 
restored during recovery.38,39
Also, TNFa and IL-1 production, as stimulated by LPS,
has been reported to be markedly decreased during attacks 
in FMF.34,36,40 We could confirm these results in three FMF 
patients and detected decreased ex vivo production of TNFa, 
IL-1/?, and IL-lra during attacks (Drenth JPH, unpublished 
observations). These findings clearly differ from the in­
creased production during the febrile attacks of the hyper- 
lgD syndrome. It is possible that the monocytes/macro­
phages in the hyper-lgD syndrome are already primed in 
vivo to produce increased amounts of these cytokines. This 
could be the result of increased concentrations of AGP and 
CRP, because these acute-phase proteins have been shown 
to potentiate the in vitro production of cytokines and of
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Fig 4. Unstimulated (upper panel) and net LPS-stimulated produc­
tion (lower panel) of IL -1«, IL-1 fi, TN Fa, IL-6, and IL-1ra in a whole  
blood culture system incubated for 24 hours. Data arè shown as the 
mean ± SD and are derived from experiments with 22 hyper-lgD  
patients during (□) and in between attacks (U) and in 10 healthy 
volunteers (□). ‘P <  .05 compared with healthy controls; " P  <  .05 
compared with values obtained between attacks.
TNFa in particular.41'43 In addition, CRP and, to lesser ex­
tent, AGP are able to induce the synthesis of IL-1 ra in vitro.43 
We have shown earlier that serum AGP concentrations are 
markedly elevated during attacks of the hyper-lgD syndrome 
and are somewhat elevated during remission.1,1 In contrast, 
lower concentrations of the acute-phase protein AGP are 
found in FMF, and this perhaps contributes to the diminished 
LPS-stimulated cytokine production.44 These data under­
score differences in pathogenesis of the disorders. Else­
where, we have already alluded to the genetic differences 
between FMF and the hyper-lgD syndrome.45 Additional 
studies are needed to further elucidate the role of the acute- 
phase proteins in cytokine regulation in the periodic fever 
syndromes and to delineate the molecular basis of the fever.
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